Serum and pleural fluid biomarkers for mesothelioma
- 1 July 2009
- journal article
- review article
- Published by Ovid Technologies (Wolters Kluwer Health) in Current Opinion in Pulmonary Medicine
- Vol. 15 (4), 366-370
- https://doi.org/10.1097/mcp.0b013e32832b98eb
Abstract
Malignant mesothelioma is an asbestos-induced, aggressive tumour. In centres across the world, research has focused on evaluating biomarkers for malignant mesothelioma screening, diagnosis, prognostication and monitoring. With the incidence of malignant mesothelioma expected to increase, it is timely to review the current status of biomarkers in this field. The majority of recent studies have evaluated the commercial MESOMARK assay in a diagnostic setting. Studies have clarified that soluble-shed mesothelin as well as mesothelin-related peptide are targets of the assay. The assay sensitivity ranges from 50% at diagnosis to 84% in advanced disease. The assay has a high level of specificity relative to benign lung and pleural conditions and is positive in 10-15% of other malignancies. In a prospective screen of 538 asbestos-exposed workers, 2.8% were positive; one had lung cancer that was subsequently successfully treated. The biomarkers megakaryocyte potentiating factor, osteopontin and CA125, either alone or in combination with soluble mesothelin, have also been assessed. To date, soluble mesothelin remains the best available biomarker for malignant mesothelioma. However, a lack of sensitivity for early-stage disease and for all malignant mesothelioma histologies provides motivation for the search of novel malignant mesothelioma biomarkers with greater sensitivity, especially for very early disease.Keywords
This publication has 43 references indexed in Scilit:
- MESOMARK kit detects C-ERC/mesothelin, but not SMRP with C-terminusBiochemical and Biophysical Research Communications, 2008
- Overexpression and altered glycosylation of MUC1 in malignant mesotheliomaBritish Journal of Cancer, 2008
- Mesothelin-related predictive and prognostic factors in malignant mesothelioma: A nested case–control studyLung Cancer, 2008
- Biomarkers for mesotheliomaCurrent Opinion in Pulmonary Medicine, 2007
- Soluble mesothelin in effusions: a useful tool for the diagnosis of malignant mesotheliomaThorax, 2007
- Mesothelin Is Shed from Tumor CellsCancer Epidemiology, Biomarkers & Prevention, 2006
- Megakaryocyte Potentiation Factor Cleaved from Mesothelin Precursor Is a Useful Tumor Marker in the Serum of Patients with MesotheliomaClinical Cancer Research, 2006
- Preoperative Sensitivity and Specificity for Early-Stage Ovarian Cancer When Combining Cancer Antigen CA-125II, CA 15-3, CA 72-4, and Macrophage Colony-Stimulating Factor Using Mixtures of Multivariate Normal DistributionsJournal of Clinical Oncology, 2004
- Invited review The cytology of malignant mesotheliomaCytopathology, 2000
- Renal carcinogenesis in the Eker ratZeitschrift für Krebsforschung und Klinische Onkologie, 1995